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Chris Twelves1, Alan Anthoney1, Claudio I. Savulsky2, Matthew Guo3, Larisa Reyderman4, Nicola Cresti5, Vladimir Semiglazov6,
Constanta Timcheva7, Ishtiaq Zubairi8, Rosemary Morrison9, Ruth Plummer5 and T. R. Jeffry Evans9,10
BACKGROUND: Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have
nonoverlapping toxicities.
METHODS: In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tumours received eribulin mesilate
intravenously in 21-day cycles according to schedule 1 (day 1) or schedule 2 (days 1, 8) with twice-daily oral capecitabine
(1000mg/m2 days 1–14). In phase 2 (dose conﬁrmation), women with advanced/MBC and ≤3 prior chemotherapies received
eribulin mesilate at the maximum tolerated dose (MTD) per the preferred schedule plus capecitabine. Primary objectives were MTD
and dose-limiting toxicities (DLTs; phase 1b) and objective response rate (ORR; phase 2). Secondary objectives included
progression-free survival (PFS), safety, and pharmacokinetics.
RESULTS: DLTs occurred in 4/19 patients (schedule 1) and 2/15 patients (schedule 2). Eribulin pharmacokinetics were dose proportional,
irrespective of schedule or capecitabine coadministration. The MTD of eribulin was 1.6mg/m2 day 1 for schedule 1 and 1.4mg/m2
days 1 and 8 for schedule 2. ORR in phase 2 (eribulin 1.4mg/m2 days 1, 8 plus capecitabine) was 43% and median PFS 7.2 months. The
most common treatment-related adverse events were neutropenia, leukopenia, alopecia, nausea, and lethargy.
CONCLUSIONS: The combination of capecitabine and eribulin showed promising efﬁcacy with manageable tolerability in patients
with MBC.
British Journal of Cancer (2019) 120:579–586; https://doi.org/10.1038/s41416-018-0366-5
INTRODUCTION
The treatment of advanced or metastatic breast cancer (MBC)
remains palliative, with little available evidence to recommend a
speciﬁc sequence of therapies.1 Both American Society of Clinical
Oncology and European Society for Medical Oncology guidelines
indicate sequential single-agent therapy as a preferred choice for
the treatment of MBC in most circumstances.1,2 However,
combination therapy often achieves higher response rates and
longer progression-free survival (PFS) than monotherapy, albeit
frequently with increased toxicity and little evidence for signiﬁcant
prolongation of overall survival (OS).3 Therefore, there remains a
need for an effective and well-tolerated combination therapy for
patients with MBC.
Eribulin mesilate (eribulin) is a novel microtubule dynamics
inhibitor with mechanisms of action distinct from that of other
conventional tubulin-targeting agents.4–6 Eribulin also causes
vascular remodelling, which may improve tumour perfusion,
leading to increased intratumoural drug penetration and
potentially enhanced efﬁcacy.7,8 Eribulin monotherapy prolongs
survival in comparison to treatment of physician’s choice in
women with previously treated MBC.9 In a randomised phase 3
trial of eribulin vs capecitabine in patients with MBC, eribulin did
not signiﬁcantly improve OS.10 However, subgroup analysis from
this study showed OS beneﬁt in various subgroups, including
patients with human epidermal growth factor receptor 2 (HER2)-
negative MBC and triple-negative MBC.11 Eribulin is approved for
the treatment of patients with MBC whose disease has progressed
after at least 1 (European Union) or 2 (United States) prior
chemotherapies for advanced/MBC, including an anthracycline
and a taxane, given at any stage of the disease.
Capecitabine is a ﬂuoropyrimidine carbamate prodrug of
5’-ﬂuorouracil (5-FU), commonly utilised as a single agent for the
treatment of patients with MBC and also in combination with other
agents, including docetaxel.12,13 Eribulin and capecitabine represent,
therefore, two of the most widely used therapies in patients with
MBC previously treated with an anthracycline and a taxane.
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Preclinical evidence in xenograft models suggests at least additive
efﬁcacy when eribulin and capecitabine are combined.14 Moreover,
prior treatment with eribulin enhanced the antitumour activity of
capecitabine in the MDA-MB-231 breast cancer xenograft model.7
Importantly, the most clinically relevant adverse events (AEs)
associated with eribulin (neutropenia, asthenia/fatigue, and periph-
eral neuropathy)9,10 are distinct from those most often seen with
capecitabine (diarrhoea and hand–foot syndrome),10,15 further
supporting the development of this combination.
We conducted a phase 1b/2 study of eribulin in combination with
capecitabine. The primary objective of phase 1b was to determine
the maximum tolerated dose (MTD) of the combination when
administered in two schedules in patients with advanced, refractory
cancer. The primary objective of phase 2, the dose-conﬁrmation
component, was to determine the objective response rate (ORR) of
the combination in patients with MBC. Secondary objectives
included safety, time to response, duration of response, duration
of stable disease, disease control rate (DCR), clinical beneﬁt rate
(CBR), PFS, and pharmacokinetic/pharmacodynamic analyses evalu-
ating a correlation of eribulin plasma concentration with changes in
cardiac repolarisation, as measured by change in Fridericia’s formula
QT correction (QTcF) from baseline.
METHODS
Patients
Dose-escalation cohorts (phase 1b). Key eligibility criteria included
patients aged ≥18 years with histologically or cytologically
conﬁrmed advanced or metastatic cancer resistant or refractory
to approved therapies. Additional eligibility criteria are sum-
marised in Supplementary Table S1.
Dose-conﬁrmation cohort (phase 2). Key eligibility criteria
included females aged ≥18 years with histologically or cytologi-
cally conﬁrmed advanced or MBC; ≤3 prior lines of chemotherapy
(sequential [neo-] adjuvant treatments counting as 1 regimen),
including an anthracycline (if appropriate) and a taxane; ≥1
measurable lesion according to Response Evaluation Criteria In
Solid Tumors (RECIST) version 1.116; adequate haematologic, liver,
and renal function; life expectancy of >3 months; and Eastern
Cooperative Oncology Group performance status of 0 or 1.
Additional eligibility criteria are summarised in Supplementary
Table S1. Prior capecitabine treatment was not allowed. Patients
with pre-existing neuropathy of grade >2 were ineligible for both
phases of the study.
Study design
This was a phase 1b/2, multicentre, open-label, dose-escalation,
and dose-conﬁrmation study (ClinicalTrials.gov, NCT01323530).
Phase 1b of the study was conducted in the United Kingdom at
3 sites with the addition of sites in Bulgaria (4) and Russia (6) for
phase 2. The phase 1b dose-escalation part had a “3+3” design.
Sequential cohorts of 3–6 patients received eribulin mesilate (2–5-
min intravenous administration) according to schedule 1 (1.2, 1.6,
or 2.0 mg/m2 [equivalent to eribulin 1.05, 1.40, and 1.75 mg/m2,
respectively, expressed as free base] on day 1 of a 21-day cycle) or
schedule 2 (0.7, 1.1, or 1.4 mg/m2 [equivalent to eribulin 0.62, 0.97,
and 1.23 mg/m2, respectively, expressed as free base] on days 1
and 8 of a 21-day cycle), in combination with twice-daily oral
capecitabine (1000 mg/m2 on days 1–14 of a 21-day cycle).
Treatment-emergent AEs (TEAEs) were deﬁned as AEs that were
new or had re-emerged and worsened in severity during
treatment or up to 30 days following the last dose of study
treatment. Toxicities were graded according to the National
Cancer Institute’s Common Terminology Criteria for Adverse
Events version 3.0. The MTD was deﬁned as the highest dose at
which no more than 1 out of 6 patients experienced a dose-
limiting toxicity (DLT), determined in phase 1b. DLTs were deﬁned
as toxicities considered to be treatment related by the investi-
gator, including grade 3 or 4 neutropenia complicated by fever
(≥38.5 °C), or grade 4 neutropenia lasting ≥7 days; grade 3
thrombocytopenia complicated by bleeding and/or requiring a
blood transfusion, or grade 4 thrombocytopenia; and ≥grade 3
non-haematologic toxicities (excluding grade 3 nausea, grade 3/4
vomiting, or diarrhoea in patients not having received antiemetic
and/or antidiarrhoeal medication), delayed recovery from
treatment-related toxicity resulting in a dose delay ≥14 days,
and failure to administer at least 75% of the planned study drugs
during cycle 1 as a result of a grade ≥2 treatment-related toxicity
that constituted an increase of at least 2 grades from baseline (i.e.
failure to receive at least 14 doses of capecitabine in schedule 1 or
failure to receive eribulin mesilate on day 8 in schedule 2). The
criteria for dose interruptions and dose modiﬁcations of both
agents are included in Supplementary Table S2.
In phase 2, patients received the preferred schedule of eribulin
selected based on tolerability and delivered dose intensity in
phase 1b. In both study phases, treatment continued until disease
progression, unacceptable toxicity, or withdrawal of consent.
Following dose reduction, dose re-escalation was not permitted.
Patients with metastatic bone disease being treated with
bisphosphonates could continue to receive bisphosphonate
therapy and the initiation of bisphosphonates after starting study
treatment was permitted upon discussion with the sponsor.
This study was conducted in accordance with national and local
Good Clinical Practice guidelines and the Declaration of Helsinki
and was approved by the relevant Institutional Review Board
ethics committees. All patients provided written informed consent
prior to participating in any study-speciﬁc procedures.
Study assessments
Tumour response per RECIST version 1.1 was assessed by the
investigator (Supplementary Table S3). The ORR was deﬁned as
the proportion of patients with a conﬁrmed complete response
(CR) or partial response (PR). Stable disease (SD) was deﬁned as SD
lasting ≥5 weeks; duration of SD was measured from time of ﬁrst
dose until progression in patients whose best response was SD.
DCR comprised CR, PR, and SD. CBR comprised CR, PR, and
SD ≥6 months.
Pharmacokinetic assessments
Blood samples were taken during cycles 1 and 2 on day 1 (pre-
dose, start of infusion, and 0.25, 0.5, 1, 2, 3, 4, 6, and 8 h after
eribulin administration), on days 2 or 3 and days 4 to 6, then on
day 8 (schedule 1: pre-dose, 0.5, 1, 2, 3, 4, and 6 h after
capecitabine administration; schedule 2: pre-dose). Plasma con-
centrations of eribulin, capecitabine, and the metabolites of
capecitabine (5-FU, 5’-deoxy-5-ﬂuorouridine, 5’-deoxy-5-ﬂuorocy-
tidine, and α-ﬂuoro-β-alanine) were measured by fully validated
methods of liquid chromatography–tandem mass spectrometry.17
Pharmacokinetic parameters, including clearance (CL; for eribulin),
area under the concentration–time curve from time zero to inﬁnity
(AUC0–∞), area under the concentration–time curve from time zero
to the time of last measurable concentration (AUC0–t), maximum
plasma concentration (Cmax), time to Cmax (tmax), and terminal
half-life (t1/2), were calculated using noncompartmental analyses
as appropriate.
To assess potential drug–drug interactions between eribulin
and capecitabine, the eribulin pharmacokinetic parameters Cmax,
CL, and AUC0–∞ were compared to historical data for eribulin
administered alone. These parameters were also compared
between cycle 1 and cycle 2 to assess for potential indirect/
time-dependent effects of capecitabine on eribulin pharmacoki-
netics. The pharmacokinetics of capecitabine were compared
between groups from schedules 1 and 2 for which, on cycle 1 day
8, an assessment of a potential for a direct PK interaction could
have been made. Capecitabine pharmacokinetics following single
A phase 1b/2, open-label, dose-escalation, and dose-conﬁrmation study. . .
C Twelves et al.
580
1
2
3
4
5
6
7
8
9
0
()
;,:
and multiple doses from the dose-escalation and intensive
pharmacokinetic sampling cohorts were compared with published
pharmacokinetic data on capecitabine.
For cardiac repolarisation analyses, individual electrocardiograms
(ECGs) were obtained in triplicate from continuous 12-lead Holter
recordings at timepoints coinciding with pharmacokinetic sample
collections. Cardiac repolarisation was measured as the duration of
the QT interval (time from QRS complex to end of T wave). QT
interval was corrected for heart rate by QTcF. Triplicate QTcF values
for each patient were averaged by timepoint to provide a single
data point per observation. The relationship between time-matched
drug concentration and change in QTcF from baseline (ΔQTcF) was
analysed using linear regression. Because capecitabine was co-
administered with eribulin, ΔQTcF could not be attributed to a single
drug or analyte; therefore, the explored concentration–QTcF
relationships were considered to be descriptive.
Statistical analyses
Of the estimated 76 patients to be treated, approximately 40
women with advanced breast cancer or MBC were to be enrolled in
the phase 2 study to enable efﬁcacy and safety evaluations. If the
ORR was 30%, a sample size of 40 patients was required to provide
2-sided 95% conﬁdence intervals (CIs) with a lower limit of 16%.
Safety analyses were based on the safety population, which
comprised all patients who received the study drug and had at
least one post-dose safety assessment; efﬁcacy analyses were
based on the full analysis set that comprised all enrolled patients
who had received at least 1 dose of the study drug. The phase
2 secondary efﬁcacy endpoints of time to response (deﬁned as the
time from the ﬁrst dose until ﬁrst documented evidence of CR or
PR), duration of response (deﬁned as the time from ﬁrst
documented evidence of CR or PR until the ﬁrst documented
sign of disease progression or death due to any cause), duration of
SD, and PFS (deﬁned as the time from the date of ﬁrst dose until
disease progression or death due to any cause) were summarised
using Kaplan–Meier plots. For DCR and CBR, the exact
Clopper–Pearson 2-sided 95% CIs were estimated.
RESULTS
Dose-escalation cohort (phase 1b)
Thirty-four patients were treated in the phase 1b study (schedule 1,
n= 19; schedule 2, n= 15; Fig. 1). Baseline demographics and
disease characteristics for patients in phase 1b are summarized in
Supplementary Table S4. With schedule 1, 1 patient had a DLT at
the 1.2-mg/m2 dose level (febrile neutropenia, grade 3); 1 had a
DLT at the 1.6-mg/m2 dose level (neutropenia, grade 4); and 2 had
a DLT at the 2.0-mg/m2 dose level (fatigue, grade 3; lethargy,
grade 3). With schedule 2, 1 patient had a DLT at the 1.1-mg/m2
dose level (neutropenic sepsis, grade 4), and another patient had a
DLT at the 1.4-mg/m2 dose level (neutropenia, grade 3). For
schedules 1 and 2, the MTDs for eribulin mesilate (in combination
with capecitabine 1000mg/m2 twice daily) were 1.6 mg/m2 on
day 1 and 1.4 mg/m2 on days 1 and 8, respectively. The planned
dose intensity for schedule 1 was 0.076 mg/m2/day and for
schedule 2 was 0.13 mg/m2/day. Because schedule 2 could
provide a better dose intensity than even the highest dose level
in schedule 1, only the MTD determined during schedule 2 was
selected for further exploration. A summary of TEAEs is provided
in Table 1; no treatment-related deaths occurred.
Patients enrolled
Dose-escalation cohort (phase 1b)a b Dose-confirmation cohort (phase 2)
N = 43
Patients treated
n = 34 Screen failures (n = 9)
Reason: 
Entry criteria (n = 3)
(n = 3)Adverse event
(n = 3)Other
Patients enrolled
N = 54
Patients treated
n = 42 Screen failures (n = 12)
Reason: 
Entry criteria (n = 10)
(n = 2)Other
Schedule 1
n = 19
Completed 13 (68%)
Disease progression 13 (68%)
Primary reason for discontinuation
from treatment:
Adverse event 2 (11%)
Patient choice 3 (16%)
Other** 1 (5%)
Schedule 2
n = 15
Completed 9 (60%)
Disease progression 9 (60%)
Discontinued 6 (32%) Discontinued 6 (40%)
Primary reason for discontinuation
from treatment:
Adverse event 2 (13%)
Patient choice 2 (13%)
Other** 2 (13%)
Dose level (eribulin mesilate)
1.2 mg/m2
1.6 mg/m2
(n = 8*)
2.0 mg/m2
(n = 6)
(n = 5)
Dose level (eribulin mesilate)
0.7 mg/m2
1.1 mg/m2
(n = 3)
1.4 mg/m2
(n = 6)
(n = 6)
*Two of the 6 patients who had received 1.2 mg/m2 did not complete cycle 1 due
to patient choice and grade 3/4 neutropenia, respectively; an additional 
2 patients were, therefore, recruited at this dose level
**Clinical progression
†Clinical progression (n = 3), investigator
decision (n = 2), development of cancer (n = 1)
n = 42
Completed 28 (67%)
Disease progression 24 (57%)
Treatment ongoing at cutoff 4 (10%)
Discontinued 14 (33%)
Primary reason for discontinuation
from treatment:
Adverse event 2 (5%)
Patient choice 6 (14%)
Other† 6 (14%)
Fig. 1 Patient disposition and primary reason for discontinuation from study treatment (combining treatment phase and extension phase)
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Pharmacokinetics and pharmacodynamics. Eribulin exposure was
dose proportional from 0.7 to 2.0 mg/m2 on day 1 of cycles 1 and
2 (Fig. 2, Supplementary Table S5). Following single-dose
administration of eribulin on cycle 1, day 1 only, mean (±SD
[standard deviation]) values for AUC0–∞ in schedule 1 ranged from
606 (±288) ng·h/mL in the 1.2 mg/m2 group to 1480 (±979) ng·h/
mL in the 1.6 mg/m2 group. In schedule 2, mean (±SD) values for
AUC0–∞ ranged from 422 (±48) ng·h/mL in the 0.7 mg/m
2 group to
785 (±258) in the 1.4 mg/m2 group (Supplementary Table S5).
Mean (±SD) AUC0–∞ in schedule 1 for eribulin in cycle 2, day 1,
ranged from 578 (±449) ng·h/mL in the 1.2 mg/m2 group to
1530 (±1120) ng·h/mL in the 1.6 mg/m2 group. In schedule 2,
mean (±SD) values for AUC0–∞ ranged from 425 (±73) ng·h/mL in
the 1.1 mg/m2 group to 686 (±110) in the 1.4 mg/m2 group
(Supplementary Table S5). The pharmacokinetics of eribulin were
independent of schedule or coadministration of capecitabine.
The pharmacokinetic-parameter estimates for capecitabine and
its metabolites were comparable between cycle 1 and cycle 2.
Coadministration with eribulin had no effect on the pharmacoki-
netics of capecitabine or its metabolites (Supplementary Fig. S1
and Table S6). Furthermore, comparable exposure was observed
across eribulin dose groups and cycles (Supplementary Fig. S1). No
correlation was seen between eribulin concentration (day 1 or day
8) and change in QTcF interval in the dose-escalation phase 1b
(Supplementary Fig. S2).
Dose-conﬁrmation cohort (phase 2)
Of the 42 patients treated in the phase 2 study (Fig. 1), 33 (79%)
had HER2-negative disease and 16 (38%) had triple-negative
disease (Table 2). All patients had received prior cancer therapy,
with 34 (81%) patients having received ≥2 regimens and all
patients having received prior anthracycline therapy (Table 2).
Thirty-three (79%) patients had received prior chemotherapy for
advanced disease. Twenty-three (55%) patients entered an
extension phase (starting at week 18) and received treatment
for as long as clinically appropriate.
The ORR was 18 out of 42 (43%; 95% CI 27.7, 59.0), with 1 CR and
17 PRs; responses were seen in patients with HER2-negative/
hormone receptor+ disease (9/17 patients), triple-negative disease
(6/16), HER2-positive disease (1/4), and HER2 unknown (2/5)
Table 1. Extent of exposure and the incidence of grade 3 and 4
treatment-related treatment-emergent adverse events reported for
each schedule (worst grade of all cycles) in the dose-escalation cohort
(phase 1b, safety analysis set)
Characteristic Schedule 1 Schedule 2
(n= 19) (n= 15)
Number of complete treatment cycles (%)
0–2 13 (68) 4 (27)
3–4 2 (11) 3 (20)
5–8 1 (5) 6 (40)
>8 2 (11) 2 (13)
Dose modiﬁcations of eribulin mesilate (%)
Dose reduction 2 (11)a 4 (27)b
Dose omission 0 4 (27)b
Dose delay 4 (21) 9 (60)c
Eribulin dose intensity at MTD (mg/m2/day)
per patient, mean (SD)
0.37 (0.6)d 0.16 (0.1)d
Grade 3/4 treatment-related TEAE (%)
Neutropenia 4 (21) 7 (47)
Lethargy 1 (5) 2 (13)
Fatigue 1 (5) 1 (7)
Febrile neutropenia 1 (5) 0
Neutropenic sepsis 0 1 (7)
Pyrexia 0 1 (7)
Palmar-plantar erythrodysaesthesia 0 1 (7)
Pulmonary embolism 0 1 (7)
QTc prolongation 0 1 (7)
Leukopenia 0 1 (7)
TEAE(s) leading to discontinuation of study drug
Febrile neutropenia 1 (5)e —
Neutropenia 1 (5)e 1 (7)f
Abnormal ECG — 1 (7)g
Data presented as n (%) unless stated otherwise. Safety analysis set: all
patients who received both study drugs and had at least 1 post-dose safety
assessment. Treatment-related TEAEs include TEAEs that were considered
by the investigator to be possibly or probably related to study drug or
TEAEs with missing causality
ECG electrocardiogram, MTD maximum tolerated dose, QTc QT interval
corrected for heart rate, SD standard deviation, TEAE treatment-emergent
adverse event
aIn the eribulin mesilate 2.0-mg/m2 cohort
b2 patients each in the eribulin mesilate 1.1- and 1.4-mg/m2 cohorts
c1, 3, and 5 patient(s) each in the eribulin mesilate 0.7-, 1.1-, and 1.4-mg/m2
cohorts, respectively
d6 patients each in the eribulin mesilate 1.6-mg/m2 (schedule 1) and
1.4-mg/m2 (schedule 2) cohorts
eGrade 3 TEAE in the eribulin mesilate 1.2-mg/m2 cohort
fGrade 4 TEAE in the eribulin mesilate 1.4-mg/m2 cohort
gGrade 1 TEAE in the eribulin mesilate 1.4-mg/m2 cohort
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Fig. 2 Mean eribulin plasma concentration–time proﬁles (phase 1b,
schedule 1, day 1; schedule 2, day 1)
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(Supplementary Table S7). Median time to response was 1.5 months,
and median duration of response was 8.6 months. SD was observed
in 16 (38%) patients, with a median duration of 5.3 months; 3 (7%)
patients had progressive disease (PD) as their best response. The
DCR was 81%, and the CBR was 57% (Supplementary Table S7).
Median PFS was 7.2 months overall (Fig. 3).
In phase 2, the median number of treatment cycles was 8
(Supplementary Table S8). Overall, 39 (93%) patients experienced
≥1 TEAE in this phase of the study, 38 (90%) of which were
reported as treatment related (Table 3). Ten (24%) patients
experienced a serious AE; and 33 (79%) patients had a grade 3 or 4
TEAE (Table 3). AEs led to dose reduction or dose interruption in
48% and 38% of patients, respectively.
Neutropenia (n= 29, 69%) and leukopenia (n= 12, 29%) were
the most common grade 3 or 4 TEAEs (Table 3), but febrile
neutropenia of grade 3 or 4 was reported in only 2 (5%) patients.
Two (5%) patients had TEAEs that led to treatment discontinua-
tion: 1 patient had deep vein thrombosis (grade 4) and pulmonary
embolism (grade 5; both considered “possibly related” to the
study drug by the investigator), and the other patient developed
peripheral sensory neuropathy (grade 3, considered “probably
related” to the study drug).
There were 3 treatment-emergent deaths in this part of the
study due to PD (n= 2) and pulmonary embolism (n= 1). QTcF
interval prolongation was observed in 3 patients (grade 2 [n= 1],
grade 3 [n= 2]), each of whom had at least 1 post-baseline
value >480ms.
DISCUSSION
In this study, the combination of eribulin mesilate administered at
the approved single-agent full dose and schedule,9,10 with
capecitabine given at a dose widely used as a single agent, was
well tolerated and active with an ORR of 43%, which is
considerably higher than the ORR of 9–12% observed for single-
agent eribulin therapy in previous studies in patients with heavily
pretreated MBC.9,10,18,19 Similarly, in patients with MBC, capecita-
bine has been associated with ORRs of 12–26% in later-line
settings10,13,20 and 30% as ﬁrst-line treatment.21 The ORR of
eribulin in combination with capecitabine in the present study
suggests additive and potentially synergistic activity of the
combination. The efﬁcacy of this combination is further supported
by a high CBR (CR, PR, and SD ≥6 months, 57%), as well as
prolonged median PFS and duration of response observed in this
study. These beneﬁts appeared to be maintained in patients with
HER2-negative and triple-negative disease. The efﬁcacy and
tolerability of the combination may reﬂect both agents being
given at, or close to, their full single-agent dosages. In addition, we
can hypothesise that the vascular remodelling that is associated
with eribulin7 may enhance the distribution and intratumoural
penetration of capecitabine and its metabolites.
Toxicities seen with the combination were consistent with the
known side effects of eribulin and capecitabine as monotherapy.
Although the incidence of TEAEs was higher than with either drug
given as a single agent,9,10,22 no new safety signal emerged with
the combination. The most frequently reported AEs were typically
managed by dose delays and reductions. Neutropenia was
generally asymptomatic, with only 2 patients experiencing febrile
neutropenia and 1 patient experiencing neutropenic sepsis in
the phase 2 part of the study. Peripheral neuropathy was
common, but only 2 (5%) patients experienced neuropathy
greater than grade 2 in phase 2. In this phase of the study,
although 79% of patients had a grade 3 or 4 TEAE, and 24% had
Table 2. Baseline patient and disease characteristics for the dose-
conﬁrmation cohort (phase 2)
Characteristic Phase 2 (n= 42)
Median age, years (range) 52.5 (32–74)
Gender, n (%)
Female 42 (100)
Race, n (%)
White 41 (98)
Black 1 (2)
ECOG PS, n (%)
0 18 (43)
1 24 (57)
Metastases at study entry, n (%)
Liver 20 (48)
Lung 24 (57)
HER2 status, n (%)
+ 4 (10)
− 33 (79)
Not done or unknown 5 (12)
Triple-negative diseasea, n (%) 16 (38)
Prior chemotherapy regimens, n (%)
1 8 (19)
2 16 (38)
3 12 (29)
>3 6 (14.3)
Prior anthracycline therapy 42 (100)
Type of prior chemotherapy, n (%)
Adjuvant 28 (66.7)
Neoadjuvant 10 (23.8)
Advanced 33 (78.6)
Median time from ﬁrst diagnosis
to study entry, months (range)
29.0 (3–181)
Median age at diagnosis, years (range) 49.0 (30–71)
Median time since last disease progression,
months (range)
1.6 (1–10)
Median duration of last therapy, months (range) 2.8 (0–106)
Best response from last therapy was not collected for this cohort
ECOG PS Eastern Cooperative Oncology Group performance status, ER oestrogen
receptor, FISH ﬂuorescence in situ hybridisation, HER2 human epidermal growth
factor receptor 2, PR progesterone receptor
aTriple-negative status deﬁned as: Yes (HER2 0/1+ or 2+ with FISH negative,
ER negative, and PR negative); and No (other cases)
Eribulin mesilate day 1 and day 8 
1.4 mg/m2 (n = 42, [events = 26])
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Fig. 3 Kaplan–Meier estimates of progression-free survival in the
dose-conﬁrmation cohort (phase 2) for all patients
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events categorised as serious, only 2 (5%) patients discontinued
treatment due to a TEAE.
Eribulin pharmacokinetics were comparable with published
data and consistent across dose levels, schedules, and treatment
cycles. Eribulin pharmacokinetics were unaffected by the
coadministration of capecitabine, indicating that there were no
drug–drug interactions. Likewise, there was no correlation
between eribulin concentration and change in the QTcF in the
dose-escalation phase of the study. In total, 5 patients in this
study developed QT prolongation (phase 1b, n= 2; phase 2, n=
3). Based on independent cardiologist review of data from
patients with QTc prolongation, all events were considered to be
caused by other factors (e.g. hypokalaemia or pre-existing heart
disease with ECG abnormalities) or were more likely related to
other factors (i.e. the time course is not suggestive of a causal
relationship). Therefore, these QTc data do not represent an
emerging safety signal.
The tolerability, treatment duration, and delivered dose
intensity of the eribulin and capecitabine combination compare
favourably with those reported in the phase 3 study of docetaxel
plus capecitabine, with remarkably similar efﬁcacy.12 The addition
of capecitabine to docetaxel improved OS and achieved an ORR of
42%; median time to progression was 6.1 months (compared to an
ORR of 43% and median PFS of 7.2 months in the current study). In
terms of toxicity, in the current study there were fewer grade 3 or
4 treatment-related TEAEs with the combination of eribulin and
capecitabine than were seen with the combination of docetaxel
and capecitabine (71% vs 96%, respectively) and less febrile
neutropenia (5% [grade 3 or 4] vs 3% [grade 3] and 13% [grade 4],
respectively.12 Treatment duration was also longer with
the eribulin and capecitabine combination than with docetaxel
and capecitabine combination (median, 5.6 vs 3.8 months,
respectively), and fewer patients required dose reductions
due to AEs (48% vs 65%, respectively).12 Therefore, we
hypothesise that the combination of eribulin and capecitabine
may offer similar efﬁcacy with lower toxicity than docetaxel
combined with capecitabine.
The limitations of the current study are its size, absence of
randomisation, and lack of quality-of-life (QOL) data. Of note, the
combination given as in the present study but with a different
capecitabine regimen was recently evaluated in another single-
arm, phase 2 feasibility study as adjuvant treatment in 77 patients
with HER2-negative, oestrogen receptor-positive early-stage
breast cancer. In that study, again the combination was feasible
and the reported AEs were consistent with the known toxicities of
each drug used alone.23 The lack of QOL data from the current
Table 3. Summary of treatment-emergent adverse events occurring in ≥10% of patients in the dose-conﬁrmation cohort (phase 2; safety analysis set)
Event TEAEs, n (%)
All grades Grades 3 or 4a Treatment relatedb Treatment related, grades 3 or 4
Patients with any TEAE 39 (93) 33 (79) 38 (90) 30 (71)
Patients with any SAE 10 (24) 7 (17) 6 (14) 4 (10)
Blood and lymphatic system disorders 35 (83) 30 (71) 34 (81) 30 (71)
Neutropenia 34 (81) 29 (69) 34 (81) 29 (69)
Leukopenia 20 (48) 12 (29) 20 (48) 12 (29)
Anaemia 11 (26) 2 (5) 5 (12) —
Gastrointestinal disorders 20 (48) 6 (14) 19 (45) 2 (4.8)
Nausea 13 (31) 2 (5) 12 (29) 1 (2.4)
Diarrhoea 9 (21) 0 8 (19) —
Vomiting 7 (17) 0 7 (17) —
Stomatitis 8 (19) 1 (2) 6 (14) 1 (2.4)
Abdominal pain 7 (17) 1 (2) 4 (10) —
General disorders and administration-site conditions 16 (38) 2 (5) 12 (29) 2 (4.8)
Pyrexia 7 (14) 0 6 (14) —
Fatigue 6 (14) 2 (5) 5 (12) 2 (4.8)
Asthenia 5 (12) 0 2 (5) —
Investigations 15 (36) 2 (5) 8 (19) 1 (2.4)
Alanine aminotransferase level increased 6 (14) 1 (2) 2 (5) 1 (2.4)
Blood lactate dehydrogenase level increased 6 (14) 0 2 (5) —
Musculoskeletal and connective tissue disorders 11 (26) 2 (5) 2 (5) 1 (2.4)c
Back pain 5 (12) 1 (2) 0 —
Nervous system disorders 17 (40) 6 (14) 14 (33) 4 (9.5)
Lethargy 8 (19) 2 (5) 8 (19) 2 (4.8)
Peripheral sensory neuropathy 6 (14) 2 (5) 6 (14) 2 (4.8)
Skin and subcutaneous tissue disorders 18 (43) 1 (2) 16 (38) —
Alopecia 15 (36) 0 15 (36) —
Palmar-plantar erythrodysaesthesia syndrome 11 (26) 1 (2) 7 (17) —
TEAE treatment-emergent adverse event
a14 (33%) experienced grade 3 TEAEs; 18 (43%) experienced grade 4 TEAEs
bIncludes TEAEs reported to be possibly or probably related to study drug, in the opinion of the investigator, or TEAEs with missing causality
c1 patient experienced treatment-related arthralgia
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study reﬂects it being a single-arm study. Interestingly, although
the addition of capecitabine to docetaxel increased the incidence
of gastrointestinal AEs and hand–foot syndrome, this did
not result in worse QOL,12 presumably because the combination
had greater anticancer efﬁcacy. Assessment of QOL will be
an important element of future trials of eribulin combined
with capecitabine.
In conclusion, eribulin and capecitabine in combination showed
promising antitumour activity in patients with MBC, with manage-
able tolerability. The combination demonstrated an ORR con-
siderably higher than the ORR observed for single-agent eribulin
therapy or capecitabine in previous studies of patients with MBC.
Despite being one of the few regimens to signiﬁcantly improve OS
in patients with MBC, the combination of docetaxel and
capecitabine is less widely used owing to toxicity concerns. The
current study suggests that eribulin in combination with
capecitabine may be an attractive option for patients in whom
combination therapy is appropriate, such as those with rapidly
progressing visceral disease. Further evaluation of the combina-
tion is warranted to establish whether it prolongs survival, without
sacriﬁcing QOL, compared to sequential single-agent chemother-
apy for patients with MBC.
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